2018-2022 | European Cooperation in Science and Technology (COST)
COST Action CA17140 entitled "Nano2Clinic: Cancer Nanomedicine - from the bench to the bedside"
NOAR
2020-2024 | European Cooperation in Science and Technology (COST)
COST Action CA19114: Network for Optimized Astatine labeled Radiopharmaceuticals
Dual-targeting iron oxide nanoparticles
2020-2021 | ΕΣΠΑ/Εκπαίδευση και Δια Βίου Μάθηση
Dual-targeting iron oxide nanoparticles against bombesin receptors (BNRs) and Prostate Specific Membrane Antigen (PSMA), radiolabeled with Gallium-68, as PET/MRI imaging agents for prostate cancer
